KZA 0.00% 37.0¢ kazia therapeutics limited

Media Interview

  1. 9,465 Posts.
    lightbulb Created with Sketch. 260
    Morgans interview with Kazia CEO Dr James Garne

    Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

    Dr Garner discusses:

    • The timeline for the next milestones for the trial of Cantrixil, a potential drug for recurrent ovarian cancer
    • Why there’s a need for treatments for the brain cancer glioblastoma multiforme, for which Kazia is developing GDC-0084
    • The company’s current cash position and burn rate


    JG states that'' KZA spend on average $750k per month on cash burn on drug development - $9m per annum around 4 min mark of interview

    Edison report recently states around $570k per month cash burn - around $7m per annum on drugs

    How is this compare with claims of drugs have little or no cost to KZA - when in actual fact they have spent a small fortune over past 4 years on these drugs ???

    How much has been spent since 2016 - 2017- 2018 and 2019 - refer annual reports etc...

    How much has GDC0084 cost so far not including purchase price and other initial payments ???


watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Mkt cap ! $23.00M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 22222 36.0¢

Sellers (Offers)

Price($) Vol. No.
37.5¢ 12525 1
View Market Depth
Last update - 16.12pm 23/08/2019 (20 minute delay) ?
0.000 ( 1.37 %)
Open High Low Volume
36.0¢ 36.0¢ 36.0¢ 1000
Last updated 14.38pm 23/08/2019 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.